Genentech expanded its Parkinson’s disease ambitions by striking a large licensing deal with Alector for AL050, an engineered enzyme replacement therapy tied to GBA1-linked glucocerebrosidase deficiency. The agreement gives Genentech exclusive global rights and sets up milestone payments that could total $1.17 billion on top of a $100 million upfront payment. AL050 is designed to address the underlying GCase deficiency rather than modulating dopamine pathways. Genentech said it will handle development, regulatory, manufacturing, and commercialization across indications, while Alector retains upside tied to progress. The deal also highlights Genentech’s broader neuroscience strategy: Alector said the upfront payment would fund additional Alzheimer’s biomarker work and push its tau and alpha-synuclein siRNA programs into IND-enabling studies.